ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Insights from 2023 ASCO® Annual Meeting

S. O'Brien, C. Coombs

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cance…

2024 ESMO Annual Meeting Insights Hub

S. Ogino

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Fixed-Duration Treatment in CLL: Current Considerations

UCI Health

E. Brem

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Palliative Medicine in Cancer Patients

Houston Methodist

E. De Leon

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

The Future of Lung Cancer Care

Yale Cancer Center

M. Davies

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

State-of-the-Art in CLL Treatment

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Cuneo

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Insights from 2023 ASH Annual Meeting

M. Shadman